Protein-tyrosine phosphatases and cancer.
Tyrosine phosphorylation is an important signalling mechanism in eukaryotic cells. In cancer, oncogenic activation of tyrosine kinases is a common feature, and novel anticancer drugs have been introduced that target these enzymes. Tyrosine phosphorylation is also controlled by protein-tyrosine phosphatases (PTPs). Recent evidence has shown that PTPs can function as tumour suppressors. In addition, some PTPs, including SHP2, positively regulate the signalling of growth-factor receptors, and can be oncogenic. An improved understanding of how these enzymes function and how they are regulated might aid the development of new anticancer agents.
Ostman
Arne
A
Cancer Center Karolinska, Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden.
Hellberg
Carina
C
Böhmer
Frank D
FD
D000818:Animals; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000201:enzymology* / Q000628:therapy; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases / Q000235:genetics / Q000378:metabolism*; D014443:Tyrosine
D014443:Tyrosine; D066246:ErbB Receptors; D017027:Protein Tyrosine Phosphatases